Alirocumab can address unmet needs in pediatric familial hypercholesterolemia: GlobalData
Praluent (alirocumab) is a monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), an enzyme that…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
metabolic disorders
Novo Nordisk to acquire Inversago Pharma for up to $1.075 bn
The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist
Dyslipidemia market to grow to $15.53 bn in 2032 across 7MM: GlobalData
Growth will be driven by the launch of therapies with promising efficacies and new mechanism of actions, as well as the growth of…
Mankind Pharma seeks CDSCO approval for Phase 1 Clinical Trials of patented anti-diabetic molecule
MKP10241 is a potent and orally administered small molecule, GPR119 agonist.